If you’ve had robotic prostate surgery, you may wonder why your prostate is sent to a laboratory afterwards when your cancer was already diagnosed before the operation. The reason is that examining the removed prostate can reveal much more detail than your biopsy was able to show.
A specialist pathologist can assess your final cancer Grade Group, how far the cancer had grown, whether it reached the surgical margins and whether the seminal vesicles or any removed lymph nodes were involved. Your specialist then considers these findings alongside your postoperative PSA to plan your follow-up and decide whether any further treatment may be needed.
Why Is Your Prostate Sent to a Laboratory After Surgery?
Your prostate is sent to a pathology laboratory so a specialist pathologist can examine the removed specimen much more extensively than was possible with your biopsy and assess your cancer in greater detail.
The results show your cancer’s Grade Group, pathological stage, local extent and surgical margins, helping your team plan your follow-up and decide whether further treatment may be needed.
Who Examines the Prostate After It Has Been Removed?
Your prostate is examined by a specialist pathologist who studies the tissue under a microscope. They assess your cancer’s type, Grade Group, pathological stage and surgical margins.
Your surgeon or cancer team will then explain what these results mean for you. The findings help guide your follow-up and whether you may need further treatment.
What Happens to the Prostate When It Reaches the Laboratory?
Once your prostate reaches the laboratory, it is carefully prepared so the pathologist can examine the cancer in detail.
- Preservation: The prostate is preserved to protect the tissue for examination.
- Surface marking: The outer surgical surface is inked to help assess the margins.
- Tissue sections: The prostate is cut into sections so different areas can be examined.
- Microscopic examination: Thin samples are studied to assess the cancer’s location, extent and margins.
This detailed examination gives your specialist more information than a biopsy alone. The findings help guide your follow-up after surgery.
What Does the Pathologist Look for?
Your pathologist confirms the type of prostate cancer present and examines how the cancer looks under the microscope. This helps your team understand exactly what was present in your prostate.
They also assess how the cancer is distributed within the prostate, its Grade Group and how far it extends. Your final pathology report therefore gives you and your doctors a clearer picture of the cancer that was removed.
What Does the Pathological Stage Tell You?
Your pathological stage shows how far your cancer had actually grown based on your removed prostate and other tissues examined after surgery. It can provide more definitive information about the local extent of your cancer than was available from scans and biopsy before treatment.
If your cancer has spread beyond your prostate or into nearby structures, your stage may be higher. This does not automatically mean your surgery has failed; it helps your specialist decide how closely you should be monitored and whether further treatment may be needed.
Why Can the Final Pathology Differ From Your Biopsy?
Your biopsy only examines small samples of your prostate, so it may not show the full extent of your cancer. Once your prostate is removed, your pathologist can examine much more tissue and may find areas that were not seen in the biopsy.
Your final Grade Group or pathological stage can therefore differ from what was expected before surgery. This does not necessarily mean your biopsy was wrong; examining the removed prostate simply gives your team more complete information about the cancer that was present.
What Are the Gleason Score and Grade Group After Surgery?
Your pathologist examines the microscopic growth pattern of your cancer and uses this to assign a Gleason score and Grade Group, which provide information about how the cancer may behave. Your result may be given as a Gleason score and an ISUP Grade Group from 1 to 5.
For example, Gleason 3+4=7 is Grade Group 2, while 4+3=7 is Grade Group 3. Your final score helps your specialist understand your cancer risk and plan your follow-up.
What Is the Dominant Tumour?
Your prostate can contain more than one separate area of cancer. Your pathologist may identify a dominant or index tumour, generally regarded as the tumour with the highest pathological stage, or the largest tumour if all of the cancer is confined to the prostate.
Information about the main tumour focus can help your team understand the distribution of cancer and compare the pathology findings with your pre-operative MRI. Having several cancer areas does not necessarily mean your cancer has spread outside your prostate.
What Is Extraprostatic Extension?
Extraprostatic extension means your prostate cancer has grown beyond the normal outer boundary of your prostate. Your pathologist may find this only under the microscope, even when your MRI did not clearly show it.
Finding it can increase your risk of recurrence, but it does not automatically mean cancer remains elsewhere in your body. Your specialist will consider it alongside your Grade Group, surgical margins, lymph nodes and postoperative PSA.
Why Are the Seminal Vesicles Examined?
Your seminal vesicles are usually removed with your prostate and examined by the pathologist. They check whether your cancer has grown into these nearby glands.
If your seminal vesicles are clear, this is generally reassuring. If cancer is found invading the seminal vesicles, this affects your pathological stage and is associated with a higher risk of recurrence. Your specialist will interpret this alongside your Grade Group, surgical margins, lymph node findings and PSA.
What Are Surgical Margins?
Your surgical margins are the surgical surfaces or cut edges of the tissue removed during your prostatectomy. Your pathologist checks these edges under a microscope to see whether any cancer cells reach the surgical surface.
A clear margin means no cancer cells reach the edge, while a positive margin means they do. Your specialist will consider this result alongside your cancer stage, Grade Group and PSA when assessing your risk and follow-up.
Does a Positive Surgical Margin Mean Cancer Was Definitely Left Behind?
No. A positive surgical margin means cancer cells reached the edge of the removed tissue, but it does not prove that cancer remains in your body.
Your specialist will consider the margin alongside your stage, Grade Group and postoperative PSA. Some men with positive margins continue to have undetectable PSA and never need further treatment.
Research Insight
A 2024 systematic review and meta-analysis by Guo and colleagues included 31 studies involving 50,028 patients after radical prostatectomy. Longer positive margins, multiple positive margins, a higher-grade cancer pattern at the margin and more advanced pathological stage were associated with a greater risk of biochemical recurrence. However, these findings describe risk across groups and cannot determine whether an individual patient with a positive margin will experience recurrence.
Why Might Your Lymph Nodes Be Sent to the Laboratory?
Your surgeon may remove pelvic lymph nodes during prostatectomy when your predicted risk of lymph node involvement makes this appropriate. These nodes are then examined by your pathologist to see whether they contain cancer cells.
If your lymph nodes are clear, this is reassuring. If cancer is found, your stage may change, and your specialist will consider this alongside your pathology and PSA when planning your follow-up.
What Other Features Can the Pathologist Identify?
Your pathology report may include terms such as cribriform architecture, intraductal carcinoma or lymphovascular invasion. These findings can provide your specialist with more information about how your cancer may behave.
You do not need to interpret these terms on your own. Your specialist will consider them alongside your Grade Group, stage, surgical margins, lymph nodes and PSA to understand your overall risk and plan your follow-up.
Evidence Note
The Royal College of Pathologists provides a UK dataset for reporting prostate cancer specimens, including radical prostatectomy specimens. Important reported features can include cancer grade, pathological stage, surgical margin status, lymphovascular invasion, invasive cribriform or intraductal carcinoma, and lymph node findings where nodes have been removed. Using a structured pathology report helps ensure that clinically important information is recorded consistently.
Does the Laboratory Measure How Much Cancer Was in the Prostate?
Your pathologist may record information about the extent or size of the cancer found in your prostate, including important tumour foci. This can add useful information about your cancer.
However, your tumour size alone does not determine your risk. Your specialist will consider it alongside your Grade Group, stage, surgical margins and other pathology findings.
What Do the Main Prostate Pathology Findings Mean?
| Pathology Finding | What It Tells You |
| Grade Group | Describes the microscopic pattern of the cancer and helps indicate its biological behaviour |
| Pathological stage | Shows how far the cancer had grown in the prostate and nearby tissues |
| Extraprostatic extension | Means cancer has extended beyond the prostate into surrounding tissue |
| Seminal vesicle invasion | Means cancer has grown into the seminal vesicles and affects pathological stage |
| Surgical margins | Show whether cancer cells reach the cut surface of the removed tissue |
| Lymph node findings | Show whether cancer cells were found in any pelvic lymph nodes that were removed |
| Cribriform architecture or intraductal carcinoma | Findings that can provide additional information about the biological behaviour and risk associated with the cancer |
| Lymphovascular invasion | Means cancer cells are identified within lymphatic or blood vessels in the specimen |
How Do Your Pathology Result and PSA Work Together?
Your pathology report tells your team what they found in the prostate and other tissues removed during surgery. Your postoperative PSA helps show whether there is biochemical evidence that prostate cancer may remain or recur after surgery.
If your pathology is reassuring and your PSA becomes undetectable, this is generally encouraging. If your pathology shows higher-risk features and your PSA remains detectable or starts rising, your specialist may investigate further and discuss whether you need additional treatment.
Can the Pathology Results Change Your Follow-Up?
Yes. Your pathology results can help your medical team understand your risk and decide how closely you need to be monitored. If your results are favourable and your PSA becomes undetectable, you may mainly need regular PSA checks.
If your cancer was higher grade, had spread beyond your prostate, involved the seminal vesicles or lymph nodes, or reached a surgical margin, you may need closer follow-up. This does not automatically mean you need further treatment, as your ongoing PSA results will also guide what happens next.
UK Guidance Note
NICE recommends PSA monitoring after radical treatment for prostate cancer, starting no earlier than six weeks after treatment. PSA should then be checked at least every six months for the first two years and at least once a year thereafter. Your pathology findings can help your specialist assess your risk, but follow-up decisions are also guided by how your PSA behaves after surgery.
Can Your Laboratory Results Lead to Further Treatment?
Yes. Your pathology results can influence whether you need further treatment, but they are not usually considered on their own. Your specialist will look at your pathology alongside your PSA and overall risk.
If your PSA remains undetectable, you may only need regular monitoring. If your PSA stays detectable or starts rising, your specialist may discuss further treatment, such as salvage radiotherapy, with hormone therapy considered in some cases.
When Will You Discuss Your Prostate Pathology Results?
Your pathology results are not usually ready straight after surgery because your prostate needs to be carefully prepared and examined. Your hospital will tell you when your results are expected and arrange a follow-up appointment.
At this appointment, you can ask about your Grade Group, stage, surgical margins, seminal vesicles and lymph nodes, if they were examined. You should also ask how these findings compare with your biopsy and MRI and what they mean for your PSA monitoring.
Myth vs Fact
| Myth | Fact |
| If your final pathology differs from your biopsy, the biopsy must have been wrong. | A biopsy samples only part of the prostate, while the removed gland can be examined much more extensively. The final Grade Group or stage can therefore change without meaning that the original biopsy was incorrectly performed. |
| A positive surgical margin proves that prostate cancer was left behind. | A positive margin means cancer cells reached the surgical surface of the removed tissue. It increases recurrence risk but does not prove that cancer remains in your body. |
| Cancer found in several areas of the prostate means it has spread elsewhere. | Prostate cancer is often multifocal, meaning several separate areas can occur within the gland. Multifocal cancer does not by itself mean that cancer has spread outside the prostate. |
| A higher pathological stage means the prostate operation was unsuccessful. | Pathological staging describes how far the cancer had grown before it was removed. A higher pathological stage can be associated with a greater risk of recurrence and can influence follow-up, but it does not by itself mean that surgery has failed. |
| Your pathology report alone decides whether you need more treatment. | Pathology is important, but your specialist also considers postoperative PSA, lymph node findings, cancer characteristics and your individual circumstances before recommending further treatment. |
Key Takeaways
- The removed prostate is examined by a histopathologist to determine the final cancer Grade Group, pathological stage, surgical margins and other important microscopic features.
- Final pathology can differ from your biopsy because the biopsy samples only part of the prostate, while the removed gland can be examined much more extensively.
- A positive surgical margin increases the risk of recurrence but does not prove that prostate cancer remains in your body.
- Seminal vesicle invasion, extraprostatic extension and cancer in pelvic lymph nodes can affect your pathological stage, recurrence risk and future follow-up.
- Your pathology results are interpreted together with your postoperative PSA rather than being used alone to decide whether further treatment is needed.
Frequently Asked Questions
1. Why Is Your Prostate Sent to a Laboratory After Robotic Surgery?
Your prostate is sent to a pathology laboratory so a specialist pathologist can examine the removed specimen much more extensively than was possible with your biopsy. This helps your team understand your cancer’s Grade Group, pathological stage, local extent and surgical margins.
2. Who Examines Your Prostate After It Has Been Removed?
A specialist pathologist examines your prostate tissue under a microscope. They assess your cancer’s type, Grade Group, pathological stage and other important features.
3. Why Can Your Final Pathology Differ From Your Biopsy?
Your biopsy examines only small samples of prostate tissue, while the removed prostate can be examined much more extensively after surgery. This means your final Grade Group or pathological stage may sometimes differ from what was expected before your operation.
4. What Do Your Gleason Score and Grade Group Tell You?
Your Gleason score and Grade Group show how your prostate cancer cells look under the microscope. Your specialist uses these results to assess your cancer risk and plan your follow-up.
5. What Does Your Pathological Stage Tell You?
Your pathological stage shows how far your cancer had grown based on the tissues removed during surgery. It can show whether the cancer had spread beyond your prostate or into nearby structures.
6. What Are Surgical Margins After Robotic Prostate Surgery?
Your surgical margins are the surgical edges of the tissue removed during prostatectomy. A clear margin means no cancer cells reach the edge, while a positive margin means cancer cells are present there.
7. Does a Positive Surgical Margin Mean Cancer Was Left Behind?
No. A positive margin means cancer cells reached the edge of the removed tissue, but it does not prove that cancer remains in your body. Your specialist will consider this alongside your PSA and other results.
8. Why Are Your Seminal Vesicles and Lymph Nodes Examined?
Your seminal vesicles and any removed lymph nodes are checked for cancer cells. These results can give your specialist more information about your cancer stage and risk.
9. How Do Your Pathology Results and PSA Work Together?
Your pathology shows what was found in the tissues removed during surgery, while your PSA helps monitor you afterwards. Your specialist will consider both when assessing your recurrence risk and planning your follow-up.
10. Can Your Pathology Results Lead to Further Treatment?
Yes, your pathology results may influence whether you need further treatment, but your PSA and overall risk also matter. If your PSA remains undetectable, you may only need regular monitoring.
Final Thoughts: What Your Prostate Pathology Results Mean for Your Next Steps
After robotic prostate surgery, your prostate is carefully examined in a pathology laboratory to provide more detailed information about the cancer that was removed. Your Grade Group, pathological stage, surgical margins, seminal vesicles and lymph nodes, if removed, can all help your specialist understand your risk and plan your follow-up.
If you are considering robotic prostate surgery in London and would like specialist advice, you can contact our team at Prostate Clinic London to discuss your treatment options and arrange a consultation tailored to your individual needs.
References:
- Royal College of Pathologists (2024) G084 Dataset for histopathology reports for prostatic carcinoma. Available at: https://www.rcpath.org/resourceLibrary/g084-dataset-for-histopathology-reports-for-prostatic-carcinoma.html
- National Institute for Health and Care Excellence (NICE) (2019, updated 2021) Prostate cancer: diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng131
- British Association of Urological Surgeons (BAUS) (2024) Robotic-assisted radical prostatectomy (RARP). Available at: https://www.baus.org.uk/patients/information_leaflets/180/radical_roboticassisted_laparoscopic_prostatectomy_rarp
- National Disease Registration Service (NDRS) (2026) Urological – Pathology. Available at: https://digital.nhs.uk/ndrs/data/data-sets/cosd/cosd-pathology-user-guide-v5.0/pathology—urology
- Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R. and Humphrey, P.A. (2016) ‘The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system’, The American Journal of Surgical Pathology, 40(2), pp. 244–252. Available at: https://pubmed.ncbi.nlm.nih.gov/26492179
- van Leenders, G.J.L.H., van der Kwast, T.H., Grignon, D.J. et al. (2020) ‘The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma’, The American Journal of Surgical Pathology, 44(8), pp. e87–e99. Available at: https://pubmed.ncbi.nlm.nih.gov/32459716
- Guo, H., Zhang, L., Shao, Y. et al. (2024) ‘The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis’, PLOS ONE, 19(7), article e0301653. Available at: https://pubmed.ncbi.nlm.nih.gov/38990870